moxonidine has been researched along with Body Weight in 10 studies
moxonidine: structure given in first source
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Moxonidine is a centrally active imidazoline receptor agonist that effectively lowers blood pressure and has been shown to have beneficial effects on lipid and carbohydrate metabolism." | 5.32 | Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. ( Marsalek, P; Sharma, AM; Wagner, T, 2004) |
| "The antihypertensive agent moxonidine, an imidazoline Ii-receptor agonist, also induces hypophagia and lowers body weight in the obese spontaneously hypertensive rat, but the central mediation of this action and the neuronal pathways that moxonidine may interact with are not known." | 3.70 | The effect of moxonidine on feeding and body fat in obese Zucker rats: role of hypothalamic NPY neurones. ( Bing, C; Brown, M; Kaan, E; King, P; Pickavance, L; Williams, G; Ziegler, D, 1999) |
| "The sympatholytic antihypertensive agent moxonidine, a centrally acting selective I1-imidazoline receptor modulator (putative agonist), may be beneficial in hypertensive patients with insulin resistance." | 3.69 | Antihypertensive agent moxonidine enhances muscle glucose transport in insulin-resistant rats. ( Fogt, DL; Gödicke, J; Henriksen, EJ; Jacob, S; Youngblood, EB, 1997) |
| "Moxonidine is a centrally active imidazoline receptor agonist that effectively lowers blood pressure and has been shown to have beneficial effects on lipid and carbohydrate metabolism." | 1.32 | Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. ( Marsalek, P; Sharma, AM; Wagner, T, 2004) |
| "Moxonidine treatment did not alter daily urinary sodium and potassium excretions, but 120 microg/kg/h moxonidine decreased urine volume after 2 days and increased cyclic guanosine 3'5'monophosphate excretion on days 4 to 7 of treatment." | 1.31 | Chronic imidazoline receptor activation in spontaneously hypertensive rats. ( El-Ayoubi, R; Gutkowska, J; Jankowski, M; Menaouar, A; Mukaddam-Daher, S, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Sayed, SS | 1 |
| Zakaria, MN | 1 |
| Abdel-Ghany, RH | 1 |
| Abdel-Rahman, AA | 1 |
| Andrade-Franzé, GM | 1 |
| Andrade, CA | 1 |
| De Luca, LA | 1 |
| De Paula, PM | 1 |
| Menani, JV | 1 |
| Menaouar, A | 1 |
| El-Ayoubi, R | 1 |
| Jankowski, M | 1 |
| Gutkowska, J | 1 |
| Mukaddam-Daher, S | 1 |
| Dikow, R | 1 |
| Kihm, LP | 1 |
| Zeier, M | 1 |
| Kapitza, J | 1 |
| Törnig, J | 1 |
| Amann, K | 1 |
| Tiefenbacher, C | 1 |
| Ritz, E | 1 |
| Sharma, AM | 1 |
| Wagner, T | 1 |
| Marsalek, P | 1 |
| Plänitz, V | 1 |
| Ernsberger, P | 1 |
| Koletsky, RJ | 1 |
| Collins, LA | 1 |
| Bedol, D | 1 |
| Mervaala, EM | 1 |
| Malmberg, L | 1 |
| Teräväinen, TL | 1 |
| Lähteenmäki, T | 1 |
| Karjala, K | 1 |
| Paakkari, I | 1 |
| Pörsti, I | 1 |
| Mest, HJ | 1 |
| Vapaatalo, H | 1 |
| Karppanen, H | 1 |
| Henriksen, EJ | 1 |
| Jacob, S | 1 |
| Fogt, DL | 1 |
| Youngblood, EB | 1 |
| Gödicke, J | 1 |
| Bing, C | 1 |
| King, P | 1 |
| Pickavance, L | 1 |
| Brown, M | 1 |
| Ziegler, D | 1 |
| Kaan, E | 1 |
| Williams, G | 1 |
1 trial available for moxonidine and Body Weight
| Article | Year |
|---|---|
Crossover comparison of moxonidine and clonidine in mild to moderate hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Body Weight; Clonidine; Creatine; Double-Blind Metho | 1984 |
9 other studies available for moxonidine and Body Weight
| Article | Year |
|---|---|
Cystathionine-γ lyase-derived hydrogen sulfide mediates the cardiovascular protective effects of moxonidine in diabetic rats.
Topics: Adiponectin; Alkynes; Animals; Baroreflex; Blood Glucose; Body Weight; Cardiotonic Agents; Cystathio | 2016 |
Lateral parabrachial nucleus and central amygdala in the control of sodium intake.
Topics: Adrenergic Antagonists; Amygdala; Angiotensin-Converting Enzyme Inhibitors; Animals; Body Weight; Ca | 2010 |
Chronic imidazoline receptor activation in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Body Weight; Female; Ge | 2002 |
Increased infarct size in uremic rats: reduced ischemia tolerance?
Topics: Animals; Body Weight; Coronary Vessels; Heart Ventricles; Hydralazine; Imidazoles; Ischemia; Male; M | 2004 |
Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Biomarkers; Blood Glucose; Blood Pressure; | 2004 |
Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholytic agent.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Eating; Female; Glucos | 1996 |
Influence of different dietary salts on the cardiovascular and renal effects of moxonidine in spontaneously hypertensive rats.
Topics: Aldosterone; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Drinking; | 1997 |
Antihypertensive agent moxonidine enhances muscle glucose transport in insulin-resistant rats.
Topics: Animals; Antihypertensive Agents; Biological Transport; Blood Glucose; Body Weight; Fatty Acids, Non | 1997 |
The effect of moxonidine on feeding and body fat in obese Zucker rats: role of hypothalamic NPY neurones.
Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Antihypertensive Agents; Blood Glucose; Body Weight; C | 1999 |